ArticleFrontiers in endocrinology2026
Association of the combined triglyceride glucose-body mass index and serum IQGAP3 in appraising coronary lesion severity in type 2 diabetes.
Article in Frontiers in endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: IQGAP3 is a novel scaffold protein involved in inflammatory and metabolic regulation and may contribute to atherosclerosis. However, its clinical significance in coronary artery disease among patients with type 2 diabetes mellitus (T2DM) remains unclear. This study investigated the association between serum IQGAP3 and coronary lesion severity and evaluated the diagnostic value of combining IQGAP3 with the triglyceride glucose-body mass index (TyG-BMI). Methods: This prospective study enrolled T2DM patients undergoing coronary angiography. Serum IQGAP3 levels were measured by enzyme-linked immunosorbent assay, and TyG-BMI was calculated using routine clinical parameters. Coronary lesion severity was assessed using the Gensini score and categorized by tertiles. Multivariable logistic regression, restricted cubic spline (RCS), subgroup, and interaction analyses were performed. ROC curves, net reclassification improvement (NRI), and integrated discrimination improvement (IDI) were used to assess model performance. Results: A total of 392 patients were included. Serum IQGAP3 levels and TyG-BMI increased significantly across Gensini score tertiles (all P< 0.05). Both IQGAP3 (OR = 3.119, 95% CI: 2.049-4.747, P< 0.001) and TyG-BMI (OR = 1.012, 95% CI: 1.003-1.021, P = 0.006) were independently associated with severe coronary stenosis. Adding TyG-BMI to the traditional risk factor model improved discrimination (AUC: 0.702 vs. 0.753; NRI = 0.180, IDI = 0.065; both P< 0.001). Further incorporation of IQGAP3 increased the AUC to 0.803 and significantly improved reclassification (NRI = 0.307, IDI = 0.138; both P< 0.001), with optimism-corrected internal validation demonstrating an AUC of 0.788 and a calibration slope of 0.926. RCS analyses demonstrated a linear positive association between IQGAP3 and disease risk, whereas TyG-BMI exhibited a nonlinear relationship. Subgroup analyses showed consistent associations across most clinical strata. Age significantly modified the association between IQGAP3 and severe coronary stenosis (Pinteraction = 0.036), with a stronger effect observed in patients younger than 65 years. Conclusion: Serum IQGAP3 and TyG-BMI are independently associated with coronary lesion severity in T2DM patients. Their combined assessment provides incremental discriminative value for coronary lesion severity and may serve as a practical, non-invasive tool for cardiovascular risk stratification.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.